Global Opioid Use Disorder Treatment Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Naloxone, Buprenorphine, and Methadone), By Sales Channel (Retail Pharmacies, Hospitals, Rehabilitation Centers), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033

Industry: Healthcare

RELEASE DATE Jan 2024
REPORT ID SI3527
PAGES 200
REPORT FORMAT PathSoft

Global Opioid Use Disorder Treatment Market Size Insights Forecasts to 2033

  • The Global Opioid Use Disorder Treatment Market Size was Valued at USD 4.2 Billion in 2023.
  • The Market Size is Growing at a CAGR of 11.52% from 2023 to 2033
  • The Worldwide Opioid Use Disorder Treatment Market Size is Expected to Reach USD 12.5 Billion by 2033
  • Asia-Pacific Expected to Grow the fastest during the Forecast Period

Global Opioid Use Disorder Treatment Market

Get more details on this report -

Request Free Sample PDF

The Global Opioid Use Disorder Treatment Market Size is Anticipated to Exceed USD 12.5 Billion by 2033, Growing at a CAGR of 11.52% From 2023 to 2033.

 

Market Overview

To avoid relapsing, the majority of patients having opioid use disorder (OUD), including people who have attained abstinence with medically supervised withdrawals or alternative approaches, may need long-term treatment. Adjunctive psychosocial treatment and medication with an opioid agonist or antagonist are the most prevalent forms of first-line treatment for people with OUD. However, it could be required to treat them only with pharmaceutical or psychosocial therapy depending on their preferences or availability. However, the necessity to fund integrated research and development initiatives that center on addiction treatment and the recovery process has been prompted by the decade-long addiction crisis. Despite the fast rate at which research on issues related to opioid use disorder has developed, stakeholders in the current treatment market landscape are gradually coming up with innovative ways to implement these discoveries in the delivery of real-world care. This is anticipated to support market expansion in the upcoming time frame. The high rate of comorbid diseases is also to blame for improper prescription medication use. Thus, during the projected period, growing overdose deaths and expanding non-medical prescription drug consumption are anticipated to fuel the global opioid use disorder treatment market expansion.

 

Report Coverage

This research report categorizes the market for the global opioid use disorder treatment market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global opioid use disorder treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global opioid use disorder treatment market.

Global Opioid Use Disorder Treatment Market Report Coverage

Report CoverageDetails
Base Year:2023
Market Size in 2023:4.2 Billion in
Forecast Period:2023-2033
Forecast Period 2023-2033 CAGR:11.52%
2033 Value Projection:12.5 Billion
Historical Data for:2019-2022
No. of Pages:200
Tables, Charts & Figures:120
Segments covered:By Drug, By Sales, and COVID-19 Impact Analysis
Companies Covered: Trevena, Titan Pharmaceuticals, Inc., BioDelivery Sciences International Inc., Novartis AG, Gamida-Cell, Opiate Pharmaceutical, Aphios, Kyowa kirin, Hikma Pharmaceuticals, MediciNova, Alkermes, Inc., and
Pitfalls & Challenges:COVID-19 Empact,Challenges, Future, Growth, & Analysis

Get more details on this report -

Request Free Sample PDF
 

Driving Factors

Expanding treatment facilities and their mergers with private recovery organizations to help provide treatment access to a wider spectrum of individuals are anticipated to drive market expansion. Moreover, it is anticipated that throughout the projection period, rising government initiatives and financing for the diagnosis and treatment of opioid use disorder would support market growth. The global opioid use disorder treatment market is being driven by a number of factors, including the rise in prescription drug abuse, the demand for addiction treatment, the need for smoking cessation therapy reimbursements, and the sharing of the harmful effects of drug use by many drug store owners.

 

Restraining Factors

The potential negative effects of the medications used to treat opioid addiction are one of the factors predicted to limit the growth of the market for treatment for opioid use disorders. These medications' common side effects, which are anticipated to impede market expansion, include nausea, vomiting, cramping in the abdomen, diarrhea, respiratory issues, pain in the bones or joints, aches in the muscles, and constipation. Furthermore, in a small number of extremely rare instances of a negative reaction, the patient may also have psychological issues including depression. It is predicted that problems such as people's reluctance to seek treatment and their abandonment of behavioral therapies, which causes relapse, will restrict the global opioid use disorder treatment market.

 

Market Segmentation

The Global Opioid Use Disorder Treatment Market share is classified into drug class, sales channel.

  • The buprenorphine segment is expected to grow at the fastest pace in the global opioid use disorder treatment market during the forecast period.   

The opioid use disorder treatment market is categorized by type into naloxone, buprenorphine, and methadone. Among these, the buprenorphine segment is expected to grow at the fastest pace in the opioid use disorder treatment market during the forecast period. This increase can be attributed to the growing use of these medications in industrialized nations such as the US and France. Additionally, the drug's beneficial formulary coverage, low risk for abuse, and relatively mild side effects, together with its high effectiveness in controlling addiction, are factors contributing to its growing popularity.

 

  • The hospital segment is expected to hold the largest share of the global opioid use disorder treatment market during the forecast period.    

Based on the sales channel the global opioid use disorder treatment market is divided into retail pharmacies, hospitals, and rehabilitation centers. The hospital segment is expected to hold the largest share of the opioid use disorder treatment market during the forecast period. Hospitals are the primary care settings with the greatest concentration of professionals and staff trained and talented individuals who help patients receive quality care. Prescription treatment uptake in clinics and hospitals also supports physician-supervised drug distribution. This is one of the main things driving opioid sales through hospital pharmacies.

 

Regional Segment Analysis of the Global Opioid Use Disorder Treatment Market

  • North America (U.S., Canada, Mexico) 
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and the Rest of South America) 
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global opioid use disorder treatment market over the predicted timeframe.

North America is projected to hold the largest share of the global opioid use disorder treatment market over the predicted years. This is due to the fact that this area is home to reputable pharmaceutical companies. In addition, as government efforts to address the rising opioid dependency continue, the market for opioid use disorder is expected to rise in the years to come. The new subcutaneous version of buprenorphine (CAM-2038) from Braeburn is intended for perhaps monthly injections. If authorized, it will be superior than Sublocade since CAM-2038 won't require starting oral buprenorphine therapy for seven days in order to achieve dosage stability, whereas Sublocade does. It is anticipated to grow the market for opioid use disorder treatment in North America.

Asia-Pacific is expected to grow at the fastest pace in the global opioid use disorder treatment market during the forecast period. The number of elderly people is growing, people are becoming more aware of healthcare services' availability, and the prevalence of chronic illnesses is rising, all of which are contributing factors to the growth. Conversely, in an effort to address China's serious drug problem, the government implemented the Methadone Maintenance Treatment program, a multimodal therapeutic strategy designed to lessen the health and social issues brought on by drug epidemics. This will contribute even more to the expansion of this area.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global opioid use disorder Treatment along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

  • Trevena
  • Titan Pharmaceuticals, Inc.
  • BioDelivery Sciences International Inc.
  • Novartis AG
  • Gamida-Cell
  • Opiate Pharmaceutical
  • Aphios
  • Kyowa kirin
  • Hikma Pharmaceuticals
  • MediciNova
  • Alkermes, Inc.

 

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Recent Developments

 

  • In October 2021, the US Food and Drug Administration (FDA) authorized Esteve Pharmaceuticals to sell SEGLENTIS (celecoxib and tramadol hydrochloride) to adults for the treatment of acute pain severe enough to call for an opioid analgesic.

 

  • In January 2022, Trevena, Inc. announced that OLINVYK (oliceridine) injection, a novel intravenous analgesic approved by the FDA for use in adults for managing acute pain severe enough to require an intravenous opioid analgesic, has been approved by the National Medical Products Administration (NMPA) of China.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Global Opioid Use Disorder Treatment Market based on the below-mentioned segments: 

 

Global Opioid Use Disorder Treatment Market, By Drug Class

  • Naloxone
  • Buprenorphine
  • Methadone

 

Global Opioid Use Disorder Treatment Market, By Sales Channel

  • Retail Pharmacies
  • Hospitals
  • Rehabilitation Centers

 

Global Opioid Use Disorder Treatment Market, By Region

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies